Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Something remarkable is happening in Chinese biotech, and it’s happening fast. The country’s drug developers are learning to ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19 th year as a premier destination for global biopharma leaders to showcase their companies and technologies ...